KDR and gastric cancer: Apatinib, a small molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2), is a first-generation oral anti-angiogenesis drug approved by the China Food and Drug Administration (CFDA) for the treatment of advanced gastric cancer.